Sabril (Vigabatrin) is an antiepileptic drug indicated for the treatment of specific types of epileptic seizures. Due to the risk of severe adverse effects such as permanent vision loss, it must be administered under the close monitoring and guidance of a physician.

Dosage and Administration of Sabril (Vigabatrin)

Refractory Complex Partial Seizures

Adults (17 years of age and older): The recommended initial dose is 1000 mg per day, administered in two divided doses (500 mg per dose).

The daily dose may be increased by 500 mg per week based on clinical response, up to the maximum recommended dose of 3000 mg per day (1500 mg twice daily).

Pediatric patients (2 to 16 years of age): The recommended dose is calculated based on body weight, with the total daily dose given in two divided doses. Pediatric patients weighing more than 60 kg should follow the adult dosing regimen.

For patients weighing 10–15 kg: Initial daily dose is 350 mg; maintenance daily dose is 1050 mg.

For patients weighing 15–20 kg: Initial daily dose is 450 mg; maintenance daily dose is 1300 mg.

For patients weighing 20–25 kg: Initial daily dose is 500 mg; maintenance daily dose is 1500 mg.

For patients weighing 25–60 kg: Initial daily dose is 500 mg; maintenance daily dose is 2000 mg.

Infantile Spasms

The initial dose is 50 mg per kg of body weight per day, administered in two divided doses (25 mg per kg per dose).

Dose adjustment: Based on clinical response, the daily dose may be increased by 25–50 mg per kg every 3 days, up to a maximum daily dose of 150 mg per kg (75 mg per kg twice daily).

Discontinuation Principles for Sabril (Vigabatrin)

Efficacy-Based Discontinuation

Refractory complex partial seizures: If no clear clinical benefit is observed within 3 months of starting treatment, discontinuation of Sabril should be considered. If signs of treatment failure appear earlier as judged clinically by the physician, the drug should be discontinued promptly.

Infantile spasms: If no substantial clinical benefit is observed within 2–4 weeks of starting treatment, Sabril should be discontinued. If signs of treatment failure emerge earlier, prompt discontinuation is also required.

Discontinuation Method

To avoid withdrawal seizures, Sabril should be tapered gradually and must not be discontinued abruptly.

Adults: The daily dose is typically reduced by 1000 mg per week until complete discontinuation.

Pediatric patients (complex partial seizures): The current daily dose should be reduced by one-third each week for three consecutive weeks.

Infants (infantile spasms): The daily dose should be reduced by 25–50 mg per kg every 3–4 days.

Dosage in Special Populations

Patients with Renal Impairment

Mild renal impairment (creatinine clearance > 50–80 mL/min): Dose should be reduced by 25%.

Moderate renal impairment (creatinine clearance > 30–50 mL/min): Dose should be reduced by 50%.

Severe renal impairment (creatinine clearance > 10–30 mL/min): Dose should be reduced by 75%.

Infants with renal impairment: Specific dose adjustment data are currently lacking, and extreme caution is required.

Pregnant Women

Based on animal data, Sabril may cause fetal harm.

Females of childbearing potential are advised to use effective contraceptive measures during treatment.

If a patient becomes pregnant or plans to become pregnant during treatment, they should consult a physician immediately.

Lactating Women

Sabril is excreted in human milk and may cause serious adverse reactions in breastfed infants; therefore, its use during lactation is not recommended.

If breastfeeding is chosen, the infant should be closely monitored for signs of vision loss, sedation, or poor sucking ability.